Digital pathology can be used to great effect in pharmaceutical research: it can accelerate analyses, give deeper insights into cellular mechanisms, and enable better understanding of their role into clinical development. This potentially offers clearer predictions on how patients may respond to treatment and lead to personalized therapies.
A newly-developed biosensor could be an alterative to MRI and mammography for breast cancer screening. The handheld device uses saliva on test strips to determine whether cancer is present.
A new US study suggests a new way to personalize mental health care: They found compounds in the blood of people with depression and suicidal ideation that could be detected using a blood test.
A team of researchers has developed a handheld, non-invasive device that can detect biomarkers for Alzheimer’s and Parkinson’s Diseases. The biosensor can also transmit the results wirelessly.
In a new study, researchers use a very large dataset to identify predictive brain imaging-based biomarkers of mental illness in adolescents.
Philips and Quibim have signed a multi-year agreement to work on an integrated solution including an AI-based software to automate real-time prostate gland segmentation in MR images.
Could a single biomarker detect all types of diseases related to dopamine deficiency in the brain? According to a Swedish research group, such a marker may have just been found.
For the first time, researchers show that AI-based predictions can deliver comparable results to clinical tests on biopsies of patients with colorectal cancer (CRC).
A new device that combines microfluidics on paper, electrochemical transduction and immunoassays on magnetic nanoparticles is useful for easy and rapid diagnosis of lung diseases.
The International Alzheimer's Congress (AAIC) in Amsterdam saw the presentation of new guidelines for diagnosing Alzheimer's disease - with blood biomarkers taking a central role.
New research suggests that combining blood biomarkers with genomic information more accurately, cost-effectively predicts the risk of developing diseases.
AI could find critical biomarkers that predict non-response to conventional treatment in patients with chronic myeloid leukaemia (CML) more quickly, researchers in Singapore find.
Damage to the brains of patients operated on for brain tumors may be assessed by measuring biomarkers in the blood pre- and postoperatively, a new study from the University of Gothenburg shows.
Researchers at the University of Campinas and the Federal University of São Carlos in Brazil have developed an electrochemical sensor that detects Parkinson's disease at different stages.
Like the better-known prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) is a biomarker that can tell physicians much about a patient's metastatic prostate cancer.
New research has found molecular signature differences in the blood of patients who fully recover from Covid-19 and those who develop long Covid.
A new blood test that can track and follow the neurodegeneration in Alzheimer's disease - and exclude other dementias.
Identification of elderly persons at risk of developing cognitive impairment and dementia could be made possible by examining ergothioneine levels in the blood, researchers from Singapore find.
With the rise of syndrome-style infections, co-infections and the current antimicrobial resistance challenges, the need for multiplexed diagnostics is now more important than ever.
Researchers from Japan have developed a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s disease, from biomarkers in blood samples.
A new study led by researchers in Barcelona has determined the protein TIMP-1 as a valuable biomarker for the progression of lung adenocarcinoma. The results open the door to new treatments.
A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity.
Researchers in Sweden have now discovered a faster and easier way to determine who has an aggressive form of prostate cancer, and who has not.
Researchers created a special ultrathin sensor, spun from gold, that can be attached directly to the skin without irritation or discomfort. The sensor can measure different biomarkers or substances to perform on-body chemical analysis.
The speedy, high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing.